In vitro skin irritation testing determines whether a chemical substance causes reversible damage to human skin using reconstructed human epidermis (RhE) models, offering a scientifically validated and regulatory-accepted alternative to traditional animal testing. This article explains the technical principle, sample requirements, testing methods, quality controls, and regulatory applications of in vitro skin irritation testing for chemicals, cosmetics, and industrial products conducted by accredited third-party laboratories.
Technical Overview
Skin irritation refers to the production of reversible damage to the skin following exposure to a chemical, characterized clinically by redness (erythema) and swelling (edema). Historically, this hazard was evaluated using the in vivo rabbit skin test (OECD Test Guideline 404). Today, in vitro skin irritation testing using reconstructed human epidermis (RhE) models is the internationally accepted stand-alone method, formally adopted as OECD Test Guideline 439.
An RhE model is a three-dimensional culture grown from human-derived epidermal keratinocytes on an inert substrate. Over several weeks of air-liquid interface culture, the keratinocytes form a multilayered, differentiated epidermis with a functional stratum corneum that closely mimics the barrier properties of native human skin. Because the test substance is applied topically, the exposure route reflects realistic human skin contact.
The test principle is quantitative cell viability assessment: chemicals that irritate the skin penetrate the stratum corneum and damage the underlying viable keratinocytes, reducing metabolic activity. Viability is measured by enzymatic conversion of MTT to a purple formazan dye, and the result is used for classification under the UN Globally Harmonized System (GHS) as either a Category 2 skin irritant or not classified for skin irritation.
Key regulatory references include OECD Test Guideline 439 (in vitro skin irritation, RhE test method), OECD Test Guideline 431 (in vitro skin corrosion, RhE test method), ISO 10993-23 (irritation testing for medical devices), the EU CLP Regulation and REACH framework, and the Chinese GB 30000 series of chemical classification standards harmonized with UN GHS. The method fully supports the 3Rs principle (replacement, reduction, and refinement of animal use) and is routinely performed by accredited third-party laboratories under GLP conditions.
Testing Samples
Liquid Chemicals
Liquid substances, including surfactant solutions, solvents, oils, acids, bases, disinfectants, and finished formulations, are applied directly onto the tissue surface. Typical application volumes range from 25 to 100 microliters per tissue depending on the validated RhE model, ensuring uniform coverage of the epidermal surface without flooding the culture.
Solid and Semi-Solid Substances
Powders, granules, waxes, polymers, gels, pastes, and cream formulations are applied at approximately 25 to 100 milligrams per tissue. To ensure adequate contact with the epidermis, solid test items are usually pre-moistened with a small volume of deionized water or buffer, and the tissue surface is gently contacted with the dosed material.
Mixtures and Multi-Component Substances
The RhE method is applicable to single chemicals as well as multi-component substances and formulated mixtures, making it suitable for industrial mixtures, agrochemical formulations, detergents, and cosmetic products. Submission of composition information and safety data sheets helps the laboratory confirm applicability.
Samples Requiring Special Handling
- Colored or strongly tinted substances that may absorb at the measurement wavelength require additional spectrophotometric interference controls.
- Reducing chemicals that directly convert MTT to formazan require frozen-killed tissue controls to correct for non-specific reduction.
- Substances with extreme pH (2.0 or below, or 11.5 and above) are generally presumed corrosive and may be classified without further testing.
- Gases, aerosols, and highly volatile substances fall outside the validated applicability domain and require alternative assessment strategies.
In general, a sample volume of 5 to 10 mL or a mass of 5 to 10 g is sufficient to complete testing, including repeats and controls. Samples should be supplied in clean, tightly sealed containers with clear labeling, batch identification, and available physicochemical information.
Testing Items
The core testing item is the in vitro skin irritation classification of a chemical using the RhE method in accordance with OECD Test Guideline 439. The following parameters and related endpoints are typically reported:
- Mean tissue viability expressed as a percentage of the concurrent negative control after MTT conversion.
- GHS classification conclusion: Category 2 skin irritant (viability at or below 50%) or no hazard classification for skin irritation (viability above 50%).
- Quality control data for the negative control (buffer or water), the positive control (typically 5% sodium dodecyl sulfate solution), and replicate tissue variability.
- Complementary in vitro endpoints when a full hazard profile is required, including skin corrosion (OECD TG 431, TG 430, TG 435) and skin sensitization screening (OECD TG 442C, 442D, 442E).
- For medical devices, irritation testing of device extracts or polar and non-polar samples in accordance with ISO 10993-23.
Testing Methods
Reconstructed Human Epidermis Test Procedure (OECD TG 439)
Validated RhE tissues are pre-incubated in assay medium to equilibrate after transport. The test chemical is applied topically to the stratum corneum surface for a defined exposure period, typically 15 to 42 minutes depending on the specific validated model and its performance standards. After exposure, the substance is thoroughly removed by rinsing with phosphate-buffered saline, and the tissues are transferred to fresh medium for a post-incubation period of approximately 42 hours, during which damage to the viable cell layers develops.
MTT Cell Viability Assay
Following post-incubation, tissues are incubated with a dilute MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, approximately 1 mg/mL) for about 3 hours. Viable keratinocytes containing active mitochondrial succinate dehydrogenase convert the yellow MTT salt into insoluble purple formazan crystals. The formazan is extracted with isopropanol, and optical density is measured spectrophotometrically at approximately 570 nm. Tissue viability is calculated relative to the negative control, and the classification threshold of 50% viability determines the irritancy outcome.
Interference Controls and Quality Assurance
- Negative control tissues treated with buffer or water must meet defined viability and optical density acceptance limits.
- Positive control tissues treated with 5% SDS must show viability below the limit defined in the model performance standards, confirming tissue sensitivity.
- For colored test items, non-specific optical density is quantified using tissues not incubated with MTT and subtracted from the result.
- For MTT-reducing test items, direct reduction is quantified using freeze-killed control tissues and corrected mathematically.
- Replicate tissues must demonstrate acceptable variability (typically a relative standard deviation below the performance standard limit) for the assay to be valid.
Testing is conducted under Good Laboratory Practice (GLP) where required for regulatory submission, with documented tissue lot quality controls, calibrated equipment, and full traceability of reagents and procedures.
Integrated Testing Strategy
In vitro skin irritation testing is usually embedded in a tiered assessment strategy. Existing data and extreme pH are evaluated first; confirmed corrosives are classified without further testing. Non-corrosive or inconclusive substances proceed to in vitro corrosion tests (OECD TG 430, TG 431, or TG 435), followed by the RhE irritation test (OECD TG 439). In vivo confirmation is reserved only for rare cases where all in vitro results are inconclusive, consistent with Integrated Approaches to Testing and Assessment (IATA) principles.
Applications
In vitro skin irritation testing results support a wide range of regulatory and commercial objectives:
- GHS, CLP, and GB 30000 series classification and labeling of chemical substances and mixtures for hazard communication and safety data sheets.
- Registration dossiers under regulatory frameworks such as REACH, new chemical substance notification in China, K-REACH in Korea, and TSCA submissions in the United States.
- Cosmetic and personal care product safety assessment under animal testing prohibition frameworks, including the EU Cosmetic Regulation.
- Biological evaluation of medical devices in accordance with the ISO 10993 series, replacing or reducing intracutaneous reactivity testing.
- Agrochemical, biocidal, and household product registration and worker safety assessment.
- Research and development screening, formulation optimization, raw material comparison, and marketing claim substantiation.
FAQ
Is the RhE test accepted as a stand-alone method by regulators? Yes. OECD Test Guideline 439 is a stand-alone, regulatory-accepted method for distinguishing GHS Category 2 skin irritants from non-classified chemicals in most major jurisdictions, including the EU under CLP and REACH. It is sufficient to waive the in vivo rabbit test for irritation in the vast majority of cases.
What is the difference between skin irritation and skin corrosion testing? Corrosion (OECD TG 431 and related guidelines) refers to irreversible tissue destruction, assessed with short exposure durations of minutes to one hour. Irritation (OECD TG 439) refers to reversible damage and uses longer exposure and post-incubation periods. The two tests are typically performed sequentially in an integrated strategy.
Can colored or MTT-reducing chemicals be tested? Yes. Dedicated controls using non-stained tissues and freeze-killed tissues quantify and correct for optical or chemical interference, allowing reliable viability calculation for most colored and reducing substances.
How long does testing take? The experimental phase, including tissue equilibration, exposure, post-incubation, and MTT measurement, is completed within about one week after sample acceptance. GLP-compliant reports are typically issued within five to ten working days after completion of the assay, depending on laboratory workflow.
Does the test identify mild irritants (GHS Category 3)? The validated prediction model distinguishes Category 2 irritants from non-classified substances. It does not reliably differentiate mild irritation (optional Category 3 in some jurisdictions), which may require weight-of-evidence assessment using additional data sources.
How should samples be submitted to an accredited third-party laboratory? Samples should be clearly labeled and accompanied by a completed application form, safety data sheet, and available physicochemical data such as pH, physical state, solubility, and color. This information allows the laboratory to confirm the applicability domain, plan interference controls, and schedule the test efficiently.